Literature DB >> 20551068

Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells.

Ponnari Gottipati1, Barbara Vischioni, Niklas Schultz, Joyce Solomons, Helen E Bryant, Tatjana Djureinovic, Natalia Issaeva, Kate Sleeth, Ricky A Sharma, Thomas Helleday.   

Abstract

Poly(ADP-ribose) (PAR) polymerase 1 (PARP1) is activated by DNA single-strand breaks (SSB) or at stalled replication forks to facilitate DNA repair. Inhibitors of PARP efficiently kill breast, ovarian, or prostate tumors in patients carrying hereditary mutations in the homologous recombination (HR) genes BRCA1 or BRCA2 through synthetic lethality. Here, we surprisingly show that PARP1 is hyperactivated in replicating BRCA2-defective cells. PARP1 hyperactivation is explained by the defect in HR as shRNA depletion of RAD54, RAD52, BLM, WRN, and XRCC3 proteins, which we here show are all essential for efficient HR and also caused PARP hyperactivation and correlated with an increased sensitivity to PARP inhibitors. BRCA2-defective cells were not found to have increased levels of SSBs, and PAR polymers formed in HR-defective cells do not colocalize to replication protein A or gammaH2AX, excluding the possibility that PARP hyperactivity is due to increased SSB repair or PARP induced at damaged replication forks. Resistance to PARP inhibitors can occur through genetic reversion in the BRCA2 gene. Here, we report that PARP inhibitor-resistant BRCA2-mutant cells revert back to normal levels of PARP activity. We speculate that the reason for the sensitivity of HR-defective cells to PARP inhibitors is related to the hyperactivated PARP1 in these cells. Furthermore, the presence of PAR polymers can be used to identify HR-defective cells that are sensitive to PARP inhibitors, which may be potential biomarkers. Copyright 2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20551068     DOI: 10.1158/0008-5472.CAN-09-4716

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  103 in total

Review 1.  The role of PARP1 in the DNA damage response and its application in tumor therapy.

Authors:  Zhifeng Wang; Fengli Wang; Tieshan Tang; Caixia Guo
Journal:  Front Med       Date:  2012-06-03       Impact factor: 4.592

2.  Re-evaluating PARP1 inhibitor in cancer.

Authors:  Alexei Tulin
Journal:  Nat Biotechnol       Date:  2011-12-08       Impact factor: 54.908

3.  Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models.

Authors:  Caroline C Clark; Jeffrey N Weitzel; Timothy R O'Connor
Journal:  Mol Cancer Ther       Date:  2012-07-09       Impact factor: 6.261

Review 4.  BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability.

Authors:  Amal Aly; Shridar Ganesan
Journal:  J Mol Cell Biol       Date:  2011-02       Impact factor: 6.216

5.  Kub5-Hera RPRD1B Deficiency Promotes "BRCAness" and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers.

Authors:  Edward A Motea; Farjana J Fattah; Ling Xiao; Luc Girard; Amy Rommel; Julio C Morales; Praveen Patidar; Yunyun Zhou; Andrew Porter; Yang Xie; John D Minna; David A Boothman
Journal:  Clin Cancer Res       Date:  2018-08-14       Impact factor: 12.531

6.  The Novel Ribonucleotide Reductase Inhibitor COH29 Inhibits DNA Repair In Vitro.

Authors:  Mei-Chuan Chen; Bingsen Zhou; Keqiang Zhang; Yate-Ching Yuan; Frank Un; Shuya Hu; Chih-Ming Chou; Chun-Han Chen; Jun Wu; Yan Wang; Xiyong Liu; D Lynne Smith; Hongzhi Li; Zheng Liu; Charles D Warden; Leila Su; Linda H Malkas; Young Min Chung; Mickey C-T Hu; Yun Yen
Journal:  Mol Pharmacol       Date:  2015-03-26       Impact factor: 4.436

7.  Non-NAD-like PARP-1 inhibitors in prostate cancer treatment.

Authors:  Yaroslava Karpova; Chao Wu; Ali Divan; Mark E McDonnell; Elizabeth Hewlett; Peter Makhov; John Gordon; Min Ye; Allen B Reitz; Wayne E Childers; Tomasz Skorski; Vladimir Kolenko; Alexei V Tulin
Journal:  Biochem Pharmacol       Date:  2019-03-15       Impact factor: 5.858

8.  Response of human prostate cancer cells and tumors to combining PARP inhibition with ionizing radiation.

Authors:  Juan Camilo Barreto-Andrade; Elena V Efimova; Helena J Mauceri; Michael A Beckett; Harold G Sutton; Thomas E Darga; Everett E Vokes; Mitchell C Posner; Stephen J Kron; Ralph R Weichselbaum
Journal:  Mol Cancer Ther       Date:  2011-05-13       Impact factor: 6.261

9.  Structure of human ADP-ribosyl-acceptor hydrolase 3 bound to ADP-ribose reveals a conformational switch that enables specific substrate recognition.

Authors:  Yasin Pourfarjam; Jessica Ventura; Igor Kurinov; Ahra Cho; Joel Moss; In-Kwon Kim
Journal:  J Biol Chem       Date:  2018-06-15       Impact factor: 5.157

10.  Coordinated Regulation of TIP60 and Poly(ADP-Ribose) Polymerase 1 in Damaged-Chromatin Dynamics.

Authors:  Masae Ikura; Kanji Furuya; Atsuhiko Fukuto; Ryo Matsuda; Jun Adachi; Tomonari Matsuda; Akira Kakizuka; Tsuyoshi Ikura
Journal:  Mol Cell Biol       Date:  2016-05-02       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.